Business Today 'Ranbaxy case not to affect Indian pharma industry'. Is everything in order in Indian pharma industry? India's pharmaceutical industry suffered twin blows recently when Ranbaxy Laboratories and Wockhardt, two of the country's biggest drug makers, came ... and more »
Pakistan Daily Times The DRAP has also increased the prices of drug import licence from Rs 250 to Rs 5,000 and the cost of capsule raw material has been surged to Rs 8,000 to Rs 250,000 for each company. Central Executive Committee member and former Pakistan ...
The Guardian Nigeria Poor local capacity to add value to available raw materials , lack of access to capital to set up processing facilities among others are some of the impediments militating against effective utilisation of local raw materials . Experts say the rich mix ...
PakistanToday.com.pk The DRAP has also increased the prices of drug import license from Rs 250 to Rs 5,000 and the cost of capsule raw material have been surged to Rs 8,000 to Rs 250,000 for each companies. Kaiser Waheed, member Central Executive Committee of and ...
Pharmaceutical Technology Magazine (blog) The increased globalization of the pharmaceutical and biopharmaceutical industries, resulting in more complex and elongated supply chains on a raw material and ingredients basis, obligates suppliers and pharmaceutical and biopharmaceutical companies ...
